WaferGen Bio-systems Announces ICELL8(TM) Single-Cell System Placements at the European Molecular Biology Laboratory and Karolinska Institutet
(Thomson Reuters ONE) -
Top-tier European Institutions to Utilize ICELL8 System for Stem Cell and
Neuroscience Research
FREMONT, Calif. and LUXEMBOURG, May 03, 2016 (GLOBE NEWSWIRE) -- WaferGen Bio-
systems (NASDAQ:WGBS) announced today that the European Molecular Biology
Laboratory (EMBL), an intergovernmental organization specializing in basic
research in the life sciences, and Karolinska Institutet, Sweden's single
largest center of medical academic research, have selected the ICELL8(TM)
Single-Cell System for use in their institutions. The system will be used for
driving innovative single-cell research in the areas of stem cell and
neuroscience research.
"The ability to assess thousands of single cells and select cells of interest
with high confidence will provide us with greater understanding of stem cell
development and differentiation," said Dr. Christophe Lancrin, Group Leader at
EMBL-Monterotondo.
"We have successfully evaluated the system's performance to ensure it meets our
stringent demands," said Sten Linnarsson, Professor at Karolinska Institutet.
"The system will enable us to accelerate our efforts in identifying and
understanding the multiple cell types of the nervous system."
"The ICELL8 Single-Cell System placements at these leading European research
centers are indicative of the growing demand we are seeing for this technology
throughout the U.S. and Europe from leading researchers in the field," said
Rollie Carlson, President and CEO WaferGen Biosystems. "These placements
represent our initial commercial foray into Europe with the ICELL8 and enhance
our position in this large target market."
The ICELL8 Single-Cell System is a revolutionary platform with the ability to
isolate thousands of single cells and process specific cells of interest for
downstream analysis using Next Generation Sequencing. The system includes an
imaging station and CellSelect(TM) software for imaging and automatic selection
of single cells for downstream processing. The system's advanced single cell
identification and selection provides greater confidence in single-cell analysis
results.
About WaferGen
WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative
genomic technology solutions for single-cell analysis and clinical research.
The ICELL8(TM) Single-Cell System is a cutting edge platform which can isolate
thousands of single cells and processes specific cells for analysis, including
Next Generation Sequencing ("NGS"). The system has demonstrated unbiased
isolation of up to 1,800 single cells ranging from 5-100 µm in size on a single
chip, including single cells from solid tumors, brain cells, pulmonary airway
cells, and multiple cell lines. The SmartChip(TM) platform can be used for
profiling and validating molecular biomarkers, and can perform massively
parallel singleplex PCR for one-step target enrichment and library preparation
for clinical NGS. The Apollo 324(TM) system can be used to process DNA and RNA
from clinical samples to NGS-ready libraries. These technologies offer a
powerful set of tools for biological analysis at the molecular and single cell
level in the life sciences, pharmaceutical, and clinical laboratory industries.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended that are intended to be covered by
the "safe harbor" created by those sections. Forward-looking statements, which
are based on certain assumptions and describe our future plans, strategies and
expectations, can generally be identified by the use of forward-looking terms
such as "believe," "expect," "may," "will," "should," "could," "seek," "intend,"
"plan," "estimate," "anticipate" or other comparable terms. Forward-looking
statements in this press release may address the following subjects among
others: statements regarding the sufficiency of our capital resources, expected
operating losses, expected revenues, expected expenses, expected cash usage, our
expectations regarding our development of future products including single cell
analysis technologies and our expectations concerning our competitive position
and business strategy. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially from those
in the forward-looking statements, as a result of various factors including
those risks and uncertainties described in the Risk Factors and in Management's
Discussion and Analysis of Financial Condition and Results of Operations
sections of our most recently filed Annual Report on Form 10-K and any
subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider
those risks and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such forward-looking
statements, which speak only as of the date made. Except as otherwise required
by the federal securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking statement
contained herein (or elsewhere) to reflect any change in our expectations with
regard thereto or any change in events, conditions or circumstances on which any
such statement is based.
INVESTOR CONTACTS:
LifeSci Advisors, LLC
Brian Ritchie
BRitchie(at)LifeSciAdvisors.com
WaferGen Bio-systems, Inc.
Rollie Carlson
Rollie.Carlson(at)wafergen.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: WaferGen Bio-systems, Inc. via GlobeNewswire
[HUG#2009691]
Unternehmensinformation / Kurzprofil:
Datum: 03.05.2016 - 23:50 Uhr
Sprache: Deutsch
News-ID 468483
Anzahl Zeichen: 6653
contact information:
Town:
FREMONT
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 380 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"WaferGen Bio-systems Announces ICELL8(TM) Single-Cell System Placements at the European Molecular Biology Laboratory and Karolinska Institutet"
steht unter der journalistisch-redaktionellen Verantwortung von
WaferGen Bio-systems, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
